Kura Oncology, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021
August 05, 2021 at 09:11 pm
Share
Kura Oncology, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced net loss was USD 33.663 million compared to USD 20.487 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.4 a year ago. For the half year, net loss was USD 64.357 million compared to USD 39.697 million a year ago. Basic loss per share from continuing operations was USD 0.97 compared to USD 0.82 a year ago.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.